Episode

Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.

Podcast
Business Of Biotech
Published
Apr 13, 2026
Duration seconds
3513
Processing state
not_requested
Canonical source
https://www.buzzsprout.com/1011661/episodes/18988960-biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d.mp3
Audio
https://www.buzzsprout.com/1011661/episodes/18988960-biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d.mp3
JSON
/v1/public/podcasts/business-of-biotech-123501/episodes/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d
Markdown
/podcast/business-of-biotech-123501/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/business-of-biotech-123501/biosimilars-and-complex-medicines-for-all-with-rna-therapeutics-sarfaraz-niazi-ph-d.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about how biosimilar regulations have taken shape, from early FDA uncertainty to citizen petitions, lawsuits, and guideline changes. Dr. Niazi offers a behind the scene look at the way FDA policy gets made, and unmade, and his own role in key regulatory changes, and legislation such as the Biologics Price Competition and Innovations Act (BPCIA), a...